|

Notfall

Thématique

Site hospitalier

Gesundheitszentrum Süd, Standort Riaz

HFR Freiburg – Kantonsspital

Clinique

Klinik für Allgemeine Innere Medizin

Contenu spécialité

Mots clés

Afficher dans la liste thématique

Oui

Gute Nachricht für Freiburger Patientinnen: Behandlung von komplexen gynäkologischen Tumoren weiterhin möglich

Die nationale Liste der Spitäler, die ab 1. Januar 2026 im Bereich der hochspezialisierten Medizin chirurgische Eingriffe an komplexen gynäkologischen Tumoren durchführen dürfen,…

Da vinci

Abteilung Kommunikation

Weiterlesen über Gute Nachricht für Freiburger Patientinnen: Behandlung von komplexen gynäkologischen Tumoren weiterhin möglich

Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations

Teaser Oncology

Weiterlesen über Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations

#19 — Burn-out: Unterstützung, Bewältigungsressourcen und Perspektiven

Gemäss dem Schweizerischen Gesundheitsobservatorium (Obsan) fühlen sich 30,3 Prozent der Bevölkerung emotional erschöpft. Fast ein Drittel leidet demnach an einem Burn-out. Dabei ist dieses Leiden nicht einmal als eigene Krankheit anerkannt.…

Burn Out - Podcast épisode 19

Abteilung Kommunikation

Weiterlesen über #19 — Burn-out: Unterstützung, Bewältigungsressourcen und Perspektiven

A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340

Teaser Oncology

Weiterlesen über A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340

Prostate Cancer Outcomes global Initiative to compare and reduce variation in localised prostate cancer

Teaser Oncology

Weiterlesen über Prostate Cancer Outcomes global Initiative to compare and reduce variation in localised prostate cancer

A randomized, multicenter, open-label, Window-of-Opportunity (WOO) trial evaluating the activity and safety of giredestrant +/- triptorelin vs. Anastrozole with triptorelin for premenopausal women with ER positive/HER negative early breast cancer (eBC)

Teaser Oncology

Weiterlesen über A randomized, multicenter, open-label, Window-of-Opportunity (WOO) trial evaluating the activity and safety of giredestrant +/- triptorelin vs. Anastrozole with triptorelin for premenopausal women with ER positive/HER negative early breast cancer (eBC)

MORNINGLYTE: A Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to CD20 Ab plus chemotherapy in subjects with previously untreated high-tumor burden fol

Teaser Oncology

Weiterlesen über MORNINGLYTE: A Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to CD20 Ab plus chemotherapy in subjects with previously untreated high-tumor burden fol

A phase 2B, randomized, blinded, placebo-controlled trial investigating the efficacy and safety of visugromab versus placebo, both in combination with pembrolizumab, pemetrexed, and CIS-/Carboplatin, in participants with newly diagnosed metastatic Non-Squ

Teaser Oncology

Weiterlesen über A phase 2B, randomized, blinded, placebo-controlled trial investigating the efficacy and safety of visugromab versus placebo, both in combination with pembrolizumab, pemetrexed, and CIS-/Carboplatin, in participants with newly diagnosed metastatic Non-Squ

Assessing physicians and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: A study in gastric and esophageal cancer

Teaser Oncology

Weiterlesen über Assessing physicians and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: A study in gastric and esophageal cancer

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Teaser Oncology

Weiterlesen über A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Onkologie abonnieren